Abstract
BACKGROUND AND AIMS: Fitusiran is a first-in-class RNA interference (RNAi) therapy that lowers antithrombin (AT) to rebalance hemostasis in people with Hemophilia A or B, with or without inhibitors. Its recent FDA approval marks a major shift toward factor-independent prophylaxis. This commentary aims to summarize the clinical evidence supporting fitusiran, highlight its therapeutic significance, and discuss its potential advantages and safety considerations. METHODS: This commentary reviews key findings from Phase 1-3 clinical trials, including ATLAS-INH and ATLAS-PPX, as well as regulatory documents and published pharmacologic evaluations. Evidence on annualized bleeding rate (ABR) reduction, thrombin generation, safety outcomes, and patient-reported benefits was synthesized to assess the impact of AT suppression on bleed prevention. RESULTS: Across clinical development, fitusiran produced substantial reductions in bleeding rates in Hemophilia A and B, irrespective of inhibitor status. Phase 1 and 2 trials demonstrated > 70%-80% AT suppression with marked increases in thrombin generation. In Phase 3 trials, median ABR decreased from 17.7 to 0.0 in ATLAS-INH and by approximately 65% in ATLAS-PPX after switching from standard prophylaxis. Many participants remained completely bleed-free. Safety findings included reversible elevations in liver enzymes, mild injection-site reactions, headaches, and rare thrombotic events, necessitating AT-level and hepatic monitoring. CONCLUSION: Fitusiran offers a transformative, once-monthly prophylactic option with broad applicability across hemophilia types and inhibitor status. Its RNAi-based, factor-independent mechanism enables durable bleed protection and improved treatment convenience. While long-term hepatic safety and thrombotic risk require continued surveillance, fitusiran represents a significant advance in hemophilia management and a promising step toward more accessible, individualized, and rebalancing-based therapies.